Product How it works Pricing Blog FAQ About Contact
Relay Therapeutics

Relay Therapeutics (NASDAQ: RLAY) revenue

Relay Therapeutics reported revenue of $15.4m for fiscal 2025, 53.4% more than in fiscal 2024 ($10.0m). Since fiscal 2020 its revenue has fallen by 81.4%, an average decline of 28.6% a year.

Relay Therapeutics's best year of the last 6 was fiscal 2020. The biggest drop was in fiscal 2021, −96.3%.

Revenue, in millions of US dollars82.720203.020211.4202225.5202310.0202415.42025
Embed this chart

Copy this code into your website or blog. The chart updates with each new annual report.

Revenue by fiscal year

Fiscal yearRevenueChangeOperating profitOperating margin
2025$15.4m+53.4%−$302.7m−1,971.6%
2024$10.0m−60.8%−$372.5m−3,722.1%
2023$25.5m+1,749.8%−$373.0m−1,460.1%
2022$1.4m−54.4%−$299.3m−21,670.9%
2021$3.0m−96.3%−$364.7m−12,040.2%
2020$82.7m—−$55.8m−67.5%

The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.

Relay Therapeutics revenue compared with its sector

By revenue for its latest fiscal year, Relay Therapeutics ranks 358th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Relay Therapeutics, 53.4%.

RankCompanyRevenueRevenue growth
356thOmniab$18.7m−29.3%
357thDianthus Therapeutics$16.1m−7.2%
358thRelay Therapeutics$15.4m53.4%
359thLineage Cell Therapeutics$14.6m53.2%
360thOpus Genetics$14.2m29.1%

Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.

Questions about the revenue of Relay Therapeutics

How much revenue did Relay Therapeutics make in fiscal 2025?
Relay Therapeutics reported revenue of $15.4m for fiscal 2025, compared with $10.0m in fiscal 2024.
How much has the revenue of Relay Therapeutics fallen?
Between fiscal 2020 and fiscal 2025 it went from $82.7m to $15.4m: 81.4% less, an average decline of 28.6% a year.
What was the best year for revenue at Relay Therapeutics?
Of its last 6 fiscal years, fiscal 2020, with $82.7m.
Where does Relay Therapeutics rank in its sector by revenue?
It ranks 358th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
Where do the figures for Relay Therapeutics come from?
From the annual report (Form 10-K) that Relay Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.

Where each figure comes from

From the annual report (Form 10-K) that Relay Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020. More on Relay Therapeutics: the Relay Therapeutics page · annual accounts · net income · insider transactions.

Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.